
Loading, please wait...

Loading, please wait...

The introduction of anti-amyloid monoclonal antibodies has fundamentally reshaped neurodegenerative therapeutics. Recent clinical practice data provide vital insights into lecanemab real-world effectiveness among Asian populations. A prospective multicenter cohort study from China recently evaluated longitudinal clinical and radiographic outcomes across nine tertiary hospitals. Specifically, investigators tracked 122 patients over a comprehensive 13-month treatment duration. These findings provide clinicians with tangible evidence regarding functional stability, amyloid plaque elimination, and real-world safety profiles. Consequently, this benchmark evidence bridges the evidentiary gap between tightly controlled registrational trials and heterogeneous everyday clinical practice.
Clinical trials often select idealized patient populations that do not represent diverse clinical practices. In contrast, this multicenter investigation enrolled 122 individuals receiving biweekly infusions of 10 mg/kg lecanemab across Southwest China. Among this representative cohort, 38.52% presented with mild cognitive impairment due to Alzheimer's disease, whereas 40.98% presented with mild dementia. Moreover, the investigators conducted 222 comprehensive follow-up visits to analyze complex disease dynamics.
To evaluate trajectory differences, researchers compared patient performance against propensity score-matched local controls and external ADNI natural-history cohorts. Consequently, linear mixed-effects models revealed that treated patients maintained remarkably stable cognitive scores throughout the 13-month observational window. Furthermore, patients demonstrated modest, favorable score fluctuations at select intermediate evaluations. Therefore, these outcomes demonstrate that structured antibody administration successfully reproduces the cognitive preservation seen in global trials. In addition, matching against external cohorts confirmed that treated patients exhibited substantially better cognitive trajectories than unmanaged historical controls.
Preserving functional independence represents the supreme objective in managing neurodegenerative dementia. Notably, 84.00% of participants maintained or improved their Clinical Dementia Rating stage after 13 months of regular treatment. This stabilization indicates substantial disease-course modification rather than mere symptomatic masking. Furthermore, treated individuals experienced slower clinical decline compared to untreated cohorts over equivalent follow-up intervals.
However, researchers noted that amyloid reduction did not demonstrate a robust statistical correlation with immediate cognitive gains across individuals. Similarly, routine baseline clinical parameters, including age and baseline functional scores, failed to predict individual treatment responses accurately. Consequently, clinicians must recognize that biomarker clearance and functional preservation follow distinct biological timelines. Therefore, clinicians should avoid relying on initial baseline metrics alone to forecast individual clinical trajectories. Instead, clinicians must evaluate cognitive stability across continuous longitudinal observations. By maintaining functional capacity, patients preserve daily executive functioning and delay institutional care needs. Thus, sustained biweekly administration effectively alters the customary downward trajectory of early neurodegenerative pathology.
Pathological accumulation of amyloid-beta plaques triggers neurotoxic cascades and downstream synaptic loss. In this prospective evaluation, investigators employed amyloid-beta positron emission tomography and computed tomography to quantify molecular clearance. After 13 months of therapy, an impressive 66.67% of participants achieved complete amyloid-negative conversion. Researchers strictly defined this status as reaching a global Centiloid value below 12.
Furthermore, quantitative imaging illustrated steady, progressive tracer clearance across key cerebral cortical regions. This rapid rate of biological conversion corroborates the robust plaque clearance observed in randomized controlled trials. Nevertheless, clinicians must understand that neurodegeneration involves parallel secondary mechanisms, including tau neurofibrillary tangle propagation and neuroinflammation. Consequently, achieving rapid amyloid negativity does not produce instantaneous cognitive recovery. Instead, plaque removal halts the primary pathological trigger, thereby providing long-term neuroprotection. Additionally, quantitative Centiloid scoring provides an indispensable tool for clinicians to measure pharmacodynamic engagement directly. Thus, molecular PET imaging objectively confirms therapeutic efficacy during routine longitudinal follow-up.
Safety monitoring represents a crucial cornerstone when administering monoclonal antibodies directed against amyloid fibrils. Amyloid-related imaging abnormalities, commonly termed ARIA, demand meticulous surveillance through structured magnetic resonance imaging protocols. In this real-world cohort, ARIA occurred in 10.66% of patients, encompassing parenchymal edema and microhemorrhages. Notably, this incidence remains slightly lower than figures reported in registrational Western trials.
Furthermore, the vast majority of observed ARIA cases remained entirely asymptomatic or clinically mild. Clinicians detected these events primarily during scheduled safety MRI scans. In addition, infusion-related reactions occurred in 5.74% of participants, with most presenting during initial doses and resolving rapidly with symptomatic management. Therefore, the treatment protocol proved broadly manageable within standard neurology specialty centers. Nevertheless, clinicians must strictly maintain regular neuroimaging schedules, particularly during the first six months of drug administration. Routine clinical vigilance ensures early radiographic identification, prompt therapeutic interruption if necessary, and safe resumption after resolution. Consequently, established safety guidelines provide effective safeguards against severe neurological complications.
Clinical trials rarely integrate caregiver evaluations directly into formal outcome matrices. However, family caregivers observe nuanced functional fluctuations that standard neuropsychological batteries frequently overlook. In this study, caregiver-reported Clinical Global Impression assessments indicated that 77.55% of participants experienced clinical improvement or sustained cognitive stability. Consequently, this strong caregiver endorsement reinforces the tangible real-world benefits felt within family units.
Nevertheless, long-term therapy persistence presented tangible operational challenges. Interestingly, therapy discontinuations did not arise primarily from drug toxicity or medical adverse events. Instead, patients and families discontinued treatment chiefly due to the logistical burden of biweekly hospital visits. Navigating intravenous infusion appointments every two weeks created profound caregiver fatigue and disruption. In addition, financial considerations and travel distances contributed to premature dropouts. Therefore, healthcare providers must address practical access barriers alongside clinical decision-making. Developing home infusion frameworks or transitioning to subcutaneous formulations could markedly enhance long-term compliance. Thus, simplifying therapeutic delivery remains critical to maximizing patient persistence in real-world clinical environments.
These 13-month findings provide valuable clinical guidance for neurologists, geriatricians, and internal medicine physicians managing early neurocognitive disorders. First, careful diagnostic verification using objective biomarkers remains non-negotiable before initiating therapy. Clinicians should confirm amyloid pathology using positron emission tomography or cerebrospinal fluid biomarker panels. Second, clinicians must educate families regarding realistic therapeutic expectations. Anti-amyloid therapies slow cognitive decline and preserve stability, rather than providing dramatic cognitive reversal.
Moreover, clinicians must implement strict magnetic resonance imaging safety monitoring at baseline and throughout initiation phases. In particular, identifying microhemorrhages and assessing apolipoprotein E genotype assists in calibrating individual risk profiles. Furthermore, healthcare teams should establish multidisciplinary workflows to support patients throughout their prolonged infusion journeys. Nursing coordination, social work support, and dedicated infusion suites minimize treatment disruption. Consequently, combining rigorous patient selection with structured safety protocols enables optimal real-world therapeutic outcomes. Thus, real-world cohort data confirm that disease-modifying therapies deliver meaningful clinical stability when applied judiciously across clinical neurology practices.
In this prospective real-world study, approximately 66.67% of treated individuals achieved amyloid-negative conversion by 13 months, defined as a Centiloid value below 12. Consequently, these findings verify robust plaque clearance outside controlled clinical trials, aligning closely with clearance rates documented in pivotal phase 3 international trials.
Amyloid-related imaging abnormalities occurred in 10.66% of patients, presenting as edema or microhemorrhages. Furthermore, most cases were mild and asymptomatic. Routine surveillance magnetic resonance imaging effectively detected these radiographic changes. As a result, clinicians managed these abnormalities successfully without significant permanent neurological morbidity or widespread premature drug discontinuation.
Interestingly, treatment discontinuation stemmed primarily from the logistical burden and inconvenience of repeated biweekly intravenous infusions rather than safety issues. Caregivers and patients frequently cited travel challenges and demanding clinic schedules. Therefore, simplifying infusion protocols and adopting subcutaneous formulations may significantly improve long-term therapeutic adherence in clinical practice.
Disclaimer: This content is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A 13-month prospective multicenter cohort study across Southwest China evaluates lecanemab in Alzheimer's disease. Results reveal cognitive stability in 84% of patients, complete amyloid clearance in 66.7%, acceptable safety with 10.66% ARIA, and favorable caregiver ratings despite infusion logistics.
Today

A Bayesian component network meta-analysis of 130 RCTs reveals that self-monitoring and gamification provide the clearest positive effects in mHealth physical activity interventions, while social comparison may have adverse psychological trade-offs.
Today

The GESS-AEEM consensus establishes a clear clinical implementation framework for testosterone therapy in postmenopausal women with hypoactive sexual desire disorder, focusing on transdermal dosing, precise laboratory monitoring, and safety communication.
Today

A multicenter observational study evaluated an 8-week digital health monitoring platform using wearable sensors in ambulatory heart failure. While participants achieved high daily wear-time of 11.7 hours and 80% completion, initial recruitment revealed significant technology-related onboarding barriers.
Today

A paired cadaveric study compared triple and quintuple percutaneous Achilles tendon lengthening. While quintuple hemisection showed numerically greater elongation, differences were not statistically significant.
Yesterday

A clinical decision-support framework using health checkup data from 231,683 adults predicts incident obesity with high discrimination (AUROC 0.918). The system integrates temporal survival analysis and risk-factor explanations to prioritize individualized preventive interventions.
Today